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according morbidity scoring to any degree (Grade 0) 
[Kirchheiner et al. 2012]. 
Several explanations for discrepancies were hypothesized in 
literature, either related to patients or related to physicians. 
On the one hand, physicians may put more emphasis in 
clinical trials on identifying severe or life threatening 
morbidity. Furthermore, it may be questioned how general or 
specific physicians ask about symptoms in follow-up due to 
time restriction and how much information of the 
communication process is altered or lost [Atkinson et al, 
2012, Vistad et al. 2008, Davidson et al. 2007]. On the other 
hand, the patients’ narrative statements about symptoms 
strongly depend on individual factors, like psychological 
coping strategies, the patient– physician relationship, 
communication factors like interpersonal sympathy and trust, 
and the setting during medical encounter [Kirchheiner et al. 
2012]. 
In conclusion, patient reported outcomes are of high 
additional value and should be incorporated in clinical trials 
as a complementary assessment to physician assessed 
morbidity in order to give a more detailed and complete 
picture of the subjective symptom burden, especially in 
situations of low grade morbidity, which may be underrated 
by physicians.  
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Well informed patients and patient advocates have a key role 
to play in the implementation of patient-centred clinical 
research strategies and approval processes, access to 
treatments and treatment optimisation approaches. In an era 
of growing demand and emphasis on both quality and 
sustainability of healthcare, it is critical to involve patients in 
the R&D process more than just being participants in trials.  
New treatments are not  just about clinical efficacy: 
Different patients want different things, e.g. better survival 
vs. other patient-relevant endpoints, managing their own 
health vs. getting guidance and being taken care 
of, maximum disease control vs. focus on maintaining quality 
of life, outpatient treatment vs. hospital-based care, ability 
to work and have a social life, impact of family and family 
planning, and many more. The pack of patient priority might 
be a key reason that a majority of clinical trials are delayed 
due to a lack of willingness to participate, and subsequently 
lack of recruitment. 
Research design and conduct requires at a very early stage to 
better understand the patients' priorities and meeting unmet 
patient needs - which can only come true by involving 
patients and patient organisations as valuable partners and in 
delivering multidisciplinary care and information. 
In many disease areas, patients are already actively engaging 
in the many processes involved in the development of new 
treatments today: from contributing to protocol design, 
informed consent and ethical review - to the overall 
medicines development process, marketing authorization and 
healthcare policy. Involving patients can accelerate research 
and make it more effective.  
But in reality, are they involved enough on a broader, 
systematic level? Is all this a myth or reality? 
This presentation will look into e.g. what patients want to 
know about clinical trials, how to turn informed consent into 
an opportunity, how patient advocates are involved in clinical 
research design today, and how patient advocates are 
trained to be knowledgeable partners for researchers. 
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Purpose/Objective: Recent Monte Carlo (MC) studies have 
shown that plastic scintillation detectors, such as the Exradin 
W1 (SI), require negligible corrections to the dose 
measurements. However, the production of Cerenkov (CRV) 
light in the optical fiber may still perturb significantly the 
measurement. A method is required to decouple the CRV 
from the scintillation signal. The purpose of this work was to 
validate the accuracy of the W1 in the measurement of 
output factors (OF) and to explore possible limitations of the 
CRV calibration procedure in small fields. 
Materials and Methods: Reading ratio (RR) measurements 
with the W1 were performed for field sizes of 0.5 x 0.5, 1 x 1 
and 2 x 2 cm2 (depth = 5 cm). The W1 was positioned 
perpendicular to the CAX (perp) in solid water (res = 3 mm) 
and parallel (//) to the CAX in water (res = 1 mm). The 
measurements were repeated 4 times, each set acquired on a 
different week. The spectrum calibration method was 
performed in each set-up to account for the CRV signal. The 
W1 RRs were compared to the expected RRs calculated using 
MC simulations of an accurate accelerator model with the 
detector modeled in the dose calculation. The RRs (//) were 
also compared to the expected OFs in water derived using: i) 
MC simulations, ii) the W1 RR (perp) deconvolved for volume 
averaging, iii) the microLion (PTW) and D1V diode (SI) RRs 
with MC correction factors applied and iv) the RRs of an 'in-
house' developed scintillator (PSD) of similar design 
characteristics to the W1. In order to explore possible 
variations of the CRV correction in small fields, varying 
lengths of the W1 and PSD optical fiber were irradiated, 
while the scintillating volume was completely shielded by 
lead blocks. Under this set-up configuration, spectral analysis 
of the PSD was performed to evaluate potential spectral 
distribution changes that may alter the CRV correction.  
Results: For the W1 RRs (//) an over-response of the level of 
3.6% was observed for the 0.5 x 0.5 cm2 relative to the 
expected MC RRs. An over-response ranging from 3% - 4.5% 
was also observed relative to the expected OFs for the 0.5 x 
0.5 cm2 (fig. 1a) The W1 RRs (perp) agreed within 1% with the 
expected MC RRs. The fiber irradiations exhibited a 
dependency of the CRV correction to the W1 irradiated fiber 
length (fig. 1b). The PSD spectral analysis did not exhibit any 
